Exact Sciences Corporation (EXAS) Shares Bought by Federated Investors Inc. PA
Federated Investors Inc. PA grew its position in Exact Sciences Corporation (NASDAQ:EXAS) by 53.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,553 shares of the medical research company’s stock after acquiring an additional 12,018 shares during the period. Federated Investors Inc. PA’s holdings in Exact Sciences Corporation were worth $1,222,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Fortaleza Asset Management Inc. bought a new position in shares of Exact Sciences Corporation in the second quarter valued at approximately $106,000. Financial Architects Inc raised its position in Exact Sciences Corporation by 90.0% in the 2nd quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after purchasing an additional 2,035 shares during the last quarter. Trexquant Investment LP bought a new position in Exact Sciences Corporation in the 2nd quarter worth approximately $216,000. Aperio Group LLC bought a new position in Exact Sciences Corporation in the 2nd quarter worth approximately $252,000. Finally, Legato Capital Management LLC bought a new position in Exact Sciences Corporation in the 2nd quarter worth approximately $254,000. Institutional investors own 85.22% of the company’s stock.
Several research analysts recently weighed in on the stock. Canaccord Genuity restated a “buy” rating and issued a $45.00 price objective on shares of Exact Sciences Corporation in a research report on Thursday, September 7th. BidaskClub upgraded shares of Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Leerink Swann set a $45.00 target price on shares of Exact Sciences Corporation and gave the stock a “buy” rating in a report on Thursday, August 24th. Zacks Investment Research lowered shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Finally, BTIG Research reaffirmed a “buy” rating and set a $45.00 target price (up previously from $35.00) on shares of Exact Sciences Corporation in a report on Monday, July 17th. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Exact Sciences Corporation presently has an average rating of “Buy” and an average target price of $40.98.
Exact Sciences Corporation (NASDAQ:EXAS) opened at 41.65 on Friday. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $43.50. The company’s market cap is $4.96 billion. The stock’s 50 day moving average is $39.88 and its 200 day moving average is $32.35.
Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The company had revenue of $57.65 million during the quarter, compared to analyst estimates of $47.73 million. Equities analysts anticipate that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.
In related news, CFO Jeffrey Thomas Elliott sold 5,846 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $39.41, for a total value of $230,390.86. Following the completion of the transaction, the chief financial officer now directly owns 19,861 shares in the company, valued at approximately $782,722.01. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP D Scott Coward sold 1,987 shares of the stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $35.21, for a total transaction of $69,962.27. Following the completion of the transaction, the senior vice president now owns 57,603 shares of the company’s stock, valued at $2,028,201.63. The disclosure for this sale can be found here. Insiders sold a total of 129,291 shares of company stock valued at $5,288,181 over the last 90 days. Company insiders own 4.00% of the company’s stock.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.